Department of Internal Medicine, McLaren Macomb Hospital, Michigan State University College of Human Medicine, 1000 Harrington St., Mt Clemens, MI 48043, USA.
Department of Neurological Surgery, Ascension Providence Hospital, Michigan State University College of Human Medicine, 16001 W Nine Mile Rd., Southfield, MI 48075, USA.
Biomolecules. 2023 Sep 15;13(9):1393. doi: 10.3390/biom13091393.
Serine protease inhibitors, SERPINS, are a highly conserved family of proteins that regulate serine proteases in the central coagulation and immune pathways, representing 2-10% of circulating proteins in the blood. Serine proteases form cascades of sequentially activated enzymes that direct thrombosis (clot formation) and thrombolysis (clot dissolution), complement activation in immune responses and also programmed cell death (apoptosis). Virus-derived serpins have co-evolved with mammalian proteases and serpins, developing into highly effective inhibitors of mammalian proteolytic pathways. Through interacting with extracellular and intracellular serine and cysteine proteases, viral serpins provide a new class of highly active virus-derived coagulation-, immune-, and apoptosis-modulating drug candidates. Viral serpins have unique characteristics: (1) function at micrograms per kilogram doses; (2) selectivity in targeting sites of protease activation; (3) minimal side effects at active concentrations; and (4) the demonstrated capacity to be modified, or fine-tuned, for altered protease targeting. To date, the virus-derived serpin class of biologics has proven effective in a wide range of animal models and in one clinical trial in patients with unstable coronary disease. Here, we outline the known viral serpins and review prior studies with viral serpins, considering their potential for application as new sources for immune-, coagulation-, and apoptosis-modulating therapeutics.
丝氨酸蛋白酶抑制剂(Serine protease inhibitors,SERPINS)是一类高度保守的蛋白质家族,可调节中心凝血和免疫途径中的丝氨酸蛋白酶,占血液中循环蛋白的 2-10%。丝氨酸蛋白酶形成级联顺序激活的酶,指导血栓形成(血栓形成)和血栓溶解(血栓溶解)、免疫反应中的补体激活以及程序性细胞死亡(细胞凋亡)。病毒衍生的丝氨酸蛋白酶与哺乳动物蛋白酶和丝氨酸蛋白酶共同进化,发展成为哺乳动物蛋白水解途径的高效抑制剂。通过与细胞外和细胞内的丝氨酸和半胱氨酸蛋白酶相互作用,病毒丝氨酸蛋白酶提供了一类新的高度活跃的病毒衍生的凝血、免疫和凋亡调节药物候选物。病毒丝氨酸蛋白酶具有独特的特点:(1)每公斤微克剂量起作用;(2)在蛋白酶激活部位具有选择性;(3)在有效浓度下副作用最小;(4)已证明能够修饰或微调,以改变蛋白酶的靶向性。迄今为止,源自病毒的丝氨酸蛋白酶类生物制剂已在广泛的动物模型和不稳定型冠心病患者的一项临床试验中证明有效。在这里,我们概述了已知的病毒丝氨酸蛋白酶,并回顾了先前关于病毒丝氨酸蛋白酶的研究,考虑了它们作为新型免疫、凝血和凋亡调节治疗药物的潜在应用。